Anti-IL6 high affinity antibody, Mouse monoclonal

clone IL6-2A3, purified from hybridoma cell culture

Anti-CTL differentiation factor (CDF), Anti-Hybridoma growth factor, Anti-B-cell stimulatory factor 2 (BSF-2), Anti-Interferon beta-2 (IFN-beta-2), Anti-Interleukin-6

Quality Level

biological source


antibody form

purified from hybridoma cell culture

antibody product type

primary antibodies


IL6-2A3, monoclonal


buffered aqueous solution

species reactivity



~1.0 mg/mL


ELISA: suitable
immunoblotting: 0.125-0.25 μg/mL using recombinant human IL6 expressed in HEK-293T cells
immunoprecipitation (IP): 10-20 μg/test using concentrated supernatant of human osteosarcoma MG-63 cells treated with IL1β



UniProt accession no.

shipped in

dry ice

storage temp.


Gene Information

human ... IL6(3569)

General description

Interleukin-6 (IL6) is a multifunctional cytokine.


recombinant human IL6


Anti-IL6 high affinity antibody, Mouse monoclonal has been used in
  • immunoblotting
  • immunoprecipitation

Biochem/physiol Actions

Interleukin-6 (IL6) plays a wide variety of important biological roles in the immune, nervous and endocrine system. It is an essential component for hybridoma growth and is found in many supplemental cloning media. IL6 regulates acute and chronic inflammatory diseases and has been proven to be an excellent target for clinical treatment against autoimmune disorders such as rheumatoid arthritis, juvenile idiopathic arthritis and Castleman′s disease. IL6 also plays a key role in the pathogenesis of multiple myeloma.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.


12 - Non Combustible Liquids

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis

Certificate of Origin

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma
Voorhees PM, et al.
British Journal of Haematology, 161(3), 357-366 (2013)
IL-6 in autoimmune disease and chronic inflammatory proliferative disease
Ishihara K and Hirano T
Cytokine & Growth Factor Reviews, 13(4-5), 357-368 (2002)
Inflammatory biomarkers in acute coronary syndromes: part I: introduction and cytokines.
Ehrin J Armstrong et al.
Circulation, 113(6), e72-e75 (2006-02-16)
L M Biasucci et al.
Circulation, 94(5), 874-877 (1996-09-01)
Elevated plasma levels of C-reactive protein have been found in the majority of patients with unstable angina. The evidence of elevated levels of acute-phase proteins in unstable angina is in line with a growing body of evidence that suggests that...
Mehmet Kocoglu et al.
Pharmaceuticals (Basel, Switzerland), 9(1) (2016-01-20)
Multiple myeloma is the second most common hematologic malignancy. The treatment of this disease has changed considerably over the last two decades with the introduction to the clinical practice of novel agents such as proteasome inhibitors and immunomodulatory drugs. Basic...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service